Recent Finacing
Recent Raise
Orionis Biosciences develops conditionally active, target‑selective cytokine biologics (A‑Kine) and a genome‑scale molecular glue discovery/design platform (Allo‑Glue) to generate targeted immunotherapies and small‑molecule degraders.
